The ELN MRD Working Party suggests a failure to reach a 3-log to 4-log reduction between the sample at diagnosis and at the end of treatment in adult patients with CBF-AML would be a relevant marker for subsequent relapse, but caution is needed whether it could be applied to children as well [50]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.